A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Inclusion Criteria:

• BMI ≥ 30.0 kilograms per square meter (kg/m²) (additional weight-relatedcomorbidities are not required for inclusion)

• BMI ≥ 27.0 kg/m² and < 30.0 kg/m² with at least one weight-related comorbidity suchas: hypertension, dyslipidemia, obstructive sleep apnea and any cardiovasculardisease

• History of at least one self-reported unsuccessful dietary or exercise effort tolose body weight

• Weight stability: self-reported change in body weight less than 5 kilograms (kg) (11pounds [lbs]) within 3 months prior to screening

Exclusion Criteria:

• Prior history or diagnosis of DM

• Presence of non-proliferative diabetic retinopathy requiring acute therapy,proliferative diabetic retinopathy or diabetic macular edema

• Have obesity induced by other endocrinologic disorders

• Participation in unbalanced/extreme diets

• Prior or planned surgical treatment for obesity

• Endoscopic and/or device-based therapy for obesity or device removal within 6 monthsprior to screening

• Have a known clinically significant gastric emptying abnormality

• Have any of the following cardiovascular conditions within 6 months prior toscreening: acute myocardial infarction, cerebrovascular accident (stroke), unstableangina, or hospitalization due to congestive heart failure (CHF)

• Have evidence of significant active, uncontrolled cardiovascular, autoimmune,endocrine, renal, hepatic, dermatological, chronic respiratory or gastrointestinaldisease, a neurological or psychiatric condition, or a history of any neuromusculardisorder or autoimmune/inflammatory disorders that may cause muscle wasting ormedical condition capable of constituting a risk when taking the study medication orinterfering with the interpretation of data, as judged by the investigator atscreening

• Have evidence of a significant, uncontrolled endocrine abnormality

• Have a history of an active or untreated malignancy or are in remission from aclinically significant malignancy

• Have evidence of a significant, active autoimmune abnormality

• Have anemia

• Have signs and symptoms of any other liver disease other than nonalcoholic fattyliver disease

• Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14units per week (females)